ViaNautis Bio

ViaNautis Bio is a private, preclinical-stage biotech founded in 2021 (spun out from UCL in 2018 as SomaServe) developing a novel non-viral delivery platform called polyNaut®. The platform's key advantages are modular targeting, payload flexibility, good tolerability, and scalable manufacturing, addressing major bottlenecks in the cell and gene therapy field. The company is bolstered by a $25M Series A financing and a strategic collaboration with Eli Lilly, positioning it to advance its pipeline for diseases with high unmet need. With an experienced leadership team and a focus on central nervous system, pulmonary, and immune system disorders, ViaNautis is targeting a significant opportunity in the growing genetic medicine market.

polyNaut® nanovesicles (PNVs): a modular, non-viral delivery system for genetic payloads with plug-and-play targeting capabilities for specific tissues/cells.

ViaNautis competes in the crowded non-viral gene delivery space, which includes companies developing lipid nanoparticles (e.g., used in mRNA vaccines), polymer-based systems, and other nanotechnologies. Its differentiation lies in the modular targeting and payload flexibility of the polyNaut® platform, specifically for hard-to-reach tissues.